Clinical Trial

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety, tolerability, efficacy and pharmacokinetics of HRS-6208 in combination with HRS-8080 ± HRS-6209, or in combination with fulvestrant ± HRS-6209, or in combination with letrozole ± HRS-6209 in patients with advanced unresectable or metastatic breast cancer.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-04
Trial Details
NCT Number NCT07389733
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Advanced Unresectable or Metastatic Breast Cancer of Adults
Enrollment 180 participants
Start Date 2026-03-27
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-03